Mutually symbiotic alliances can often lead to great medicines
Advancing the frontier of any new field is rarely an individual pursuit, but this is especially true in biotechnology. To that end EXUMA Biotechnology is collaborating—and seeking out new partnerships—with those who share our mission of providing breakthrough, yet accessible, global cancer solutions.
EXUMA Biotech provides an experienced blend of innovative discovery and translational medicine within a framework of quality standards and regulatory science. Our comprehensive, data-driven approach to candidate design and selection provides an optimized and efficient process to select the best CAR composition for a given indication amongst hundreds of thousands of rationally designed combinations, while applying equal innovation to technologies that enable scalability and global patient access to our solutions.
Our Partners
- PerHum Therapeutics
- Moffitt Cancer Center
PerHum Therapeutics
Shanghai PerHum Therapeutics Co., Ltd, a company incorporated in Shanghai in 2016, focuses on developing innovative cancer treatments in the field of adoptive cellular therapies. PerHum is partnered with Shanghai EXUMA Biotechnology, Ltd. The core business of the company is the clinical development of EXUMA’s TMR CAR-T technology in Greater China. By investing in and building the GMP facility for virus packaging and cell processing needed for TMR CAR-T cell therapy, PerHum Therapeutics supports the clinical trials in solid tumors, collaborating with some of the leading hospitals in China.
Moffitt Cancer Center
EXUMA Biotech and Moffitt Cancer Center have entered into a strategic collaboration to develop EXUMA’s first rapid point-of-care, or “rPOC”, subcutaneous (SC) CAR-TaNK product for the treatment of B cell malignancies without preparative chemotherapy. Moffitt will provide regulatory support, gene product characterization, and analytical testing to support first-in-human studies. The collaboration enables EXUMA and Moffitt to further characterize and validate the rPOC SC technology and qualify analytical testing for product and patient screening to support IND submission.
